As of Jul 18
| -1.57 / -5.83%|
The 10 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 32.50, with a high estimate of 35.00 and a low estimate of 24.00. The median estimate represents a +28.26% increase from the last price of 25.34.
The current consensus among 10 polled investment analysts is to Buy stock in Cara Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.